[8-K] Bluejay Diagnostics, Inc. Reports Material Event
Bluejay Diagnostics, Inc. furnished a Current Report stating that, following its quarterly report for the fiscal quarter ended June 30, 2025, the company issued a press release providing a 2025 second quarter business and corporate update.
The press release is furnished as Exhibit 99.1 and the cover page interactive data file is included as Exhibit 104. The filing specifies the information is being furnished and is not "filed" under the Exchange Act and will not be incorporated by reference into other filings unless identified. The report was signed by Neil Dey, President and Chief Executive Officer.
Bluejay Diagnostics, Inc. ha presentato un Current Report in cui comunica che, a seguito del proprio rapporto trimestrale relativo al periodo fiscale conclusosi il 30 giugno 2025, la società ha diffuso un comunicato stampa contenente un aggiornamento aziendale e societario per il secondo trimestre 2025.
Il comunicato è fornito come Allegato 99.1 e il file interattivo della pagina di copertina è incluso come Allegato 104. Il documento specifica che le informazioni sono fornite e non sono "filed" ai sensi dell'Exchange Act e non saranno incorporate per riferimento in altri documenti, salvo diversa indicazione. Il rapporto è stato firmato da Neil Dey, Presidente e Amministratore Delegato.
Bluejay Diagnostics, Inc. presentó un Current Report en el que indica que, tras su informe trimestral correspondiente al período fiscal finalizado el 30 de junio de 2025, la compañía emitió un comunicado de prensa con una actualización comercial y corporativa del segundo trimestre de 2025.
El comunicado se adjunta como Anexo 99.1 y el archivo de datos interactivo de la portada se incluye como Anexo 104. La presentación aclara que la información se suministra y no está "filed" en virtud del Exchange Act y no se incorporará por referencia en otros documentos salvo que se indique lo contrario. El informe fue firmado por Neil Dey, Presidente y Director Ejecutivo.
Bluejay Diagnostics, Inc.는 Current Report를 제출하여, 회계분기가 2025년 6월 30일로 종료되는 분기의 분기보고서에 이어 회사가 2025년 2분기 사업 및 기업 업데이트를 담은 보도자료를 발표했다고 밝혔습니다.
해당 보도자료는 Exhibit 99.1로 제공되며 표지 페이지의 인터랙티브 데이터 파일은 Exhibit 104로 포함되어 있습니다. 제출 서류에는 이 정보가 제공(furnished)된 것이며 Exchange Act에 따라 "filed"된 것이 아니며, 별도 표기가 없는 한 다른 제출 문서에 참조로 포함되지 않는다고 명시되어 있습니다. 이 보고서는 Neil Dey 대표이사 겸 최고경영자가 서명했습니다.
Bluejay Diagnostics, Inc. a transmis un Current Report indiquant que, suite à son rapport trimestriel pour la période fiscale close le 30 juin 2025, la société a publié un communiqué de presse fournissant une mise à jour commerciale et d'entreprise pour le deuxième trimestre 2025.
Le communiqué est fourni en tant que Exhibit 99.1 et le fichier de données interactif de la page de couverture est inclus en tant que Exhibit 104. Le dépôt précise que les informations sont fournies (furnished) et ne sont pas "filed" au titre de l'Exchange Act et ne seront pas incorporées par référence dans d'autres documents sauf indication contraire. Le rapport a été signé par Neil Dey, Président et Chief Executive Officer.
Bluejay Diagnostics, Inc. hat einen Current Report eingereicht, in dem mitgeteilt wird, dass das Unternehmen nach seinem Quartalsbericht für das am 30. Juni 2025 endende Geschäftsjahr eine Pressemitteilung mit einem Geschäfts- und Konzernupdate für das zweite Quartal 2025 veröffentlicht hat.
Die Pressemitteilung ist als Exhibit 99.1 beigefügt und die interaktive Datendatei der Titelseite ist als Exhibit 104 enthalten. In der Einreichung wird ausdrücklich angegeben, dass die Informationen geliefert (furnished) werden und nicht im Sinne des Exchange Act "filed" sind und nicht in andere Einreichungen durch Verweis aufgenommen werden, sofern nicht anders angegeben. Der Bericht wurde von Neil Dey, Präsident und Chief Executive Officer, unterzeichnet.
- None.
- None.
Insights
Routine Regulation FD disclosure; no financial metrics provided, so immediate investor impact appears neutral.
The filing furnishes a press release with a second quarter business and corporate update but contains no earnings figures, financial tables, or transaction details. Because the company explicitly states the release is furnished rather than filed and will not be incorporated by reference unless specified, there is no new audited financial information or formal amendment to prior filings in this report. Investors seeking material financial data will need to refer to the quarterly report referenced in the filing or the furnished press release itself.
Disclosure aligns with Regulation FD procedures; furnishing indicates public communication but does not change filing status.
The company followed disclosure protocol by furnishing the press release as Exhibit 99.1 and including the interactive data file as Exhibit 104. The report clarifies the press release is furnished and not filed, preserving limits on incorporation by reference. The document is signed by the CEO, indicating proper corporate authorization for the submission. From a governance perspective, this is a procedural, compliant disclosure rather than a material governance event.
Bluejay Diagnostics, Inc. ha presentato un Current Report in cui comunica che, a seguito del proprio rapporto trimestrale relativo al periodo fiscale conclusosi il 30 giugno 2025, la società ha diffuso un comunicato stampa contenente un aggiornamento aziendale e societario per il secondo trimestre 2025.
Il comunicato è fornito come Allegato 99.1 e il file interattivo della pagina di copertina è incluso come Allegato 104. Il documento specifica che le informazioni sono fornite e non sono "filed" ai sensi dell'Exchange Act e non saranno incorporate per riferimento in altri documenti, salvo diversa indicazione. Il rapporto è stato firmato da Neil Dey, Presidente e Amministratore Delegato.
Bluejay Diagnostics, Inc. presentó un Current Report en el que indica que, tras su informe trimestral correspondiente al período fiscal finalizado el 30 de junio de 2025, la compañía emitió un comunicado de prensa con una actualización comercial y corporativa del segundo trimestre de 2025.
El comunicado se adjunta como Anexo 99.1 y el archivo de datos interactivo de la portada se incluye como Anexo 104. La presentación aclara que la información se suministra y no está "filed" en virtud del Exchange Act y no se incorporará por referencia en otros documentos salvo que se indique lo contrario. El informe fue firmado por Neil Dey, Presidente y Director Ejecutivo.
Bluejay Diagnostics, Inc.는 Current Report를 제출하여, 회계분기가 2025년 6월 30일로 종료되는 분기의 분기보고서에 이어 회사가 2025년 2분기 사업 및 기업 업데이트를 담은 보도자료를 발표했다고 밝혔습니다.
해당 보도자료는 Exhibit 99.1로 제공되며 표지 페이지의 인터랙티브 데이터 파일은 Exhibit 104로 포함되어 있습니다. 제출 서류에는 이 정보가 제공(furnished)된 것이며 Exchange Act에 따라 "filed"된 것이 아니며, 별도 표기가 없는 한 다른 제출 문서에 참조로 포함되지 않는다고 명시되어 있습니다. 이 보고서는 Neil Dey 대표이사 겸 최고경영자가 서명했습니다.
Bluejay Diagnostics, Inc. a transmis un Current Report indiquant que, suite à son rapport trimestriel pour la période fiscale close le 30 juin 2025, la société a publié un communiqué de presse fournissant une mise à jour commerciale et d'entreprise pour le deuxième trimestre 2025.
Le communiqué est fourni en tant que Exhibit 99.1 et le fichier de données interactif de la page de couverture est inclus en tant que Exhibit 104. Le dépôt précise que les informations sont fournies (furnished) et ne sont pas "filed" au titre de l'Exchange Act et ne seront pas incorporées par référence dans d'autres documents sauf indication contraire. Le rapport a été signé par Neil Dey, Président et Chief Executive Officer.
Bluejay Diagnostics, Inc. hat einen Current Report eingereicht, in dem mitgeteilt wird, dass das Unternehmen nach seinem Quartalsbericht für das am 30. Juni 2025 endende Geschäftsjahr eine Pressemitteilung mit einem Geschäfts- und Konzernupdate für das zweite Quartal 2025 veröffentlicht hat.
Die Pressemitteilung ist als Exhibit 99.1 beigefügt und die interaktive Datendatei der Titelseite ist als Exhibit 104 enthalten. In der Einreichung wird ausdrücklich angegeben, dass die Informationen geliefert (furnished) werden und nicht im Sinne des Exchange Act "filed" sind und nicht in andere Einreichungen durch Verweis aufgenommen werden, sofern nicht anders angegeben. Der Bericht wurde von Neil Dey, Präsident und Chief Executive Officer, unterzeichnet.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation or Organization) | (Commission File No.) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices and zip code)
(
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On August 7, 2025, following the filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025, Bluejay Diagnostics, Inc. issued a press release providing a 2025 second quarter business and corporate update. A copy of that press release is furnished with this report as Exhibit 99.1.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| 99.1 |
Press release, dated August 7, 2025 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Bluejay Diagnostics, Inc. | ||
| By: | /s/ Neil Dey | |
| Neil Dey | ||
| President and Chief Executive Officer | ||
Date: August 8, 2025
2
FAQ
What did Bluejay Diagnostics (BJDX) disclose in this 8-K?
When was the press release issued?
Is the press release considered filed with the SEC?
Which exhibits are included with the 8-K (BJDX)?
Who signed the Form 8-K for Bluejay Diagnostics?
